Hypertension

Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma

Retrieved on: 
Thursday, March 7, 2024
T cell, Glioblastoma, Arms, ICT, ICV, Traffic barrier, Toxicity, Headache, Biopsy, DSM-IV codes, Cerebrospinal fluid, City, Cancer, Central nervous system, CXCL10, TME, Cerebral edema, Dual, Hope, GBM, Safety, CXCL9, Fatigue, Hypertension, Translation, CNS, Tumor microenvironment, Patient, Arm, Spinal cord, Survival, Brain, Nature Medicine, Infrared spectroscopy correlation table, Vaccine

WORCESTER, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced Phase 1 clinical data were published in Nature Medicine that demonstrated the promising safety and clinical activity of Mustang’s MB-101 (IL13Ra2-targeted CAR T-cells) for the treatment of patients with recurrent and refractory malignant glioma, including glioblastoma.

Key Points: 
  • MB-101 was developed by City of Hope, one of the largest cancer research and treatment organizations in the United States, and exclusively licensed to Mustang.
  • Central nervous system (CNS) increases in inflammatory cytokines, including IFNγ, CXCL9, and CXCL10, were associated with CAR T-cell administration and bioactivity.
  • Primary endpoints were safety and feasibility, with secondary endpoints measuring therapy-related cytokine dynamics, CAR T-cell persistence and clinical outcomes.
  • Dr. Brown has a financial interest in Mustang and has previously been a paid consultant for the company.

Teladoc Health Expands Obesity & Weight Management Capabilities

Retrieved on: 
Thursday, March 7, 2024
Pharmacy, Diabetes, Mental health, Recurrence, Obesity, Health, C-peptide, Weight loss, Sleep, Stroke, TDOC, Type 2 diabetes, Hypertension, Teladoc Health, Health insurance

The multidisciplinary care model is designed by clinicians experienced in obesity medicine and delivered with a tailored approach to weight management.

Key Points: 
  • The multidisciplinary care model is designed by clinicians experienced in obesity medicine and delivered with a tailored approach to weight management.
  • Clients can provide their populations with comprehensive and integrated clinical care, that also addresses wellbeing, mental health and social drivers of health in a personalized manner,” said Dr. Vidya Raman-Tangella, Teladoc Health Chief Medical Officer.
  • The Comprehensive Weight Management solution is customized for health plans and employers to meet the needs of their populations and reduce the cost of care for obesity-related medical expenses by going beyond care coordination to deliver:
    An evidence-based, personally tailored approach inclusive of comprehensive support from providers experienced in obesity management, health coaching, medical nutrition therapy, and integrated, highly accessible mental health support.
  • More information on Teladoc Health’s obesity and weight management programs can be found here .

Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients

Retrieved on: 
Wednesday, March 6, 2024
Blood pressure, PV, HOPE, Beat (music), Overalls, Cardiac output, Stroke, Safety, Hypertension, Aorta, Patient, Hemodynamics, RV, DDD, Heart failure, Medical device

These data demonstrate the favorable impact of AVIM therapy compared to standard right ventricular (RV) pacing on systolic blood pressure and overall cardiac function when delivered using both conduction system andstandard pacing lead locations.

Key Points: 
  • These data demonstrate the favorable impact of AVIM therapy compared to standard right ventricular (RV) pacing on systolic blood pressure and overall cardiac function when delivered using both conduction system andstandard pacing lead locations.
  • The PV loop study was conducted at Na Homolce Hospital in Prague by Prof. Petr Neužil, M.D.
  • AVIM therapy is an investigational patented bioelectronic therapy, administered using a standard dual-chamber pacemaker, designed to immediately, substantially and persistently reduce blood pressure.
  • “Well-conducted invasive PV loop studies are a robust way to evaluate the impact of a novel therapy like AVIM on hemodymanics and overall cardiac function.

The Joint Commission, Kaiser Permanente announce application period for 2024 Bernard J. Tyson National Award for Excellence in Pursuit of Healthcare Equity

Retrieved on: 
Tuesday, March 5, 2024
Hypertension, Woman, Pregnancy, Joint Commission, University, Disability, Organization, Patient, Health, Black, Kaiser Permanente, Joint, Plague

OAKBROOK TERRACE, Illinois, March 05, 2024 (GLOBE NEWSWIRE) -- The Joint Commission and Kaiser Permanente are now accepting applications for the 2024 Bernard J. Tyson National Award for Excellence in Pursuit of Healthcare Equity.

Key Points: 
  • OAKBROOK TERRACE, Illinois, March 05, 2024 (GLOBE NEWSWIRE) -- The Joint Commission and Kaiser Permanente are now accepting applications for the 2024 Bernard J. Tyson National Award for Excellence in Pursuit of Healthcare Equity.
  • The award program will recognize a healthcare organization that led an initiative that achieved a measurable, sustained reduction in one or more disparities.
  • Bernard J. Tyson, the late CEO and chairman of Kaiser Permanente, worked tirelessly to address the disparities that plague the U.S. healthcare system.
  • Learn more about The Joint Commission’s and Kaiser Permanente’s commitments to healthcare equity.

Season Health Announces Partnership with Steward Health Care Network, Providing Food-as-Medicine Programs to Address Hypertension and Nutrition Insecurity

Retrieved on: 
Tuesday, March 5, 2024
ACO, Incidence, Cardiovascular disease, Massachusetts health care reform, Steward, Food, Risk, Hypertension, Patient, Health equity, Medicaid, Partnership, Pharmaceutical industry

Austin, TX, March 05, 2024 (GLOBE NEWSWIRE) -- Season Health, the leading food-as-medicine platform designed to address chronic condition management at scale, today announced a partnership with Steward Health Care Network, the largest physician-led private for-profit health care network in the United States.

Key Points: 
  • Austin, TX, March 05, 2024 (GLOBE NEWSWIRE) -- Season Health, the leading food-as-medicine platform designed to address chronic condition management at scale, today announced a partnership with Steward Health Care Network, the largest physician-led private for-profit health care network in the United States.
  • The partnership includes two comprehensive programs in Massachusetts: the first is focused on patients with hypertension and the second supports Medicaid patients with chronic conditions who are experiencing nutrition insecurity.
  • “This partnership with Season reflects our commitment to meeting the nutrition needs of our members and addressing health equity for our members across Massachusetts,” said Jennie Vital, Director, Medicaid ACO at Steward.
  • “Season's evidence-based programs ensure that clinical care and medically-tailored food are both affordable and accessible, supporting improved outcomes for our members.”

Molecular Templates, Inc. Provides Interim Update

Retrieved on: 
Monday, March 4, 2024
Therapy, Head, Neoplasm, Neck, CLS, AML, Part, TME, Sale, Pembrolizumab, Multiple myeloma, Bristol Myers Squibb, Symantec Endpoint Protection, TPS, Hyponatremia, Cytokine, Hypertension, Tumor microenvironment, Patient, Immunoglobulin A, MD Anderson Cancer Center, Hyperlipidemia, Disease, Biology, HNSCC, Hypercholesterolemia, CPS, PD-L1, Cancer, Pharmaceutical industry

Unique pharmacodynamic effects demonstrating potent Treg clearance and IL-2 increases were observed at the first dose level.

Key Points: 
  • Unique pharmacodynamic effects demonstrating potent Treg clearance and IL-2 increases were observed at the first dose level.
  • MTEM intends to initiate a study of MT-0169 in CD38+ acute leukemias in collaboration with MD Anderson Cancer Center.
  • Additional details on each of these participant’s clinical profile and response to the investigational treatment are provided below.
  • MTEM plans on initiating an investigator sponsored trial with MD Anderson Cancer Center to evaluate MT-0169 in relapsed or refractory CD38+ AML patients.

ACADEMY OF NUTRITION AND DIETETICS CELEBRATES BEYOND THE TABLE FOR 2024 NATIONAL NUTRITION MONTH® IN MARCH

Retrieved on: 
Thursday, February 29, 2024
Diabetes, CNAME record, Restaurant, Food storage, Dietitian, Nutrition, RDN, SNAP, Education, Farmer, WIC, Sale, Conditional sentence, Food, Health, School, Hypertension, Patient, Table, Environment, Research

Chicago, Feb. 29, 2024 (GLOBE NEWSWIRE) -- The Academy of Nutrition and Dietetics kicks off its annual National Nutrition Month® campaign on March 1.

Key Points: 
  • Chicago, Feb. 29, 2024 (GLOBE NEWSWIRE) -- The Academy of Nutrition and Dietetics kicks off its annual National Nutrition Month® campaign on March 1.
  • National Nutrition Month® started in 1973 as National Nutrition Week, and it became a month-long observance in 1980 in response to growing interest in nutrition.
  • Representing more than 112,000 credentialed nutrition and dietetics practitioners, the Academy of Nutrition and Dietetics is the world’s largest organization of food and nutrition professionals.
  • The Academy is committed to improving health and advancing the profession of dietetics through research, education and advocacy.

LiveCare Inc.(OTCMKTS: LVCE) Enters Hypertension Market, Enhancing Healthcare Monitoring for U.S. Adults

Retrieved on: 
Wednesday, February 28, 2024
Diabetes, Stroke, Blood pressure, Heart, Physician, Conditional sentence, Growth, Loneliness, Splenic infarction, Prevalence, Health, Hypertension, Head, Happiness, Patient, Public

This device represents a significant step forward in combating high blood pressure, a prevalent condition affecting roughly one-third of adults in the United States.

Key Points: 
  • This device represents a significant step forward in combating high blood pressure, a prevalent condition affecting roughly one-third of adults in the United States.
  • A distinguishing feature of the LiveCare Health approach is the real-time transmission of device readings to the health center.
  • The demand for blood pressure monitoring devices is substantial and expanding, fueled by growing recognition of the critical role of early hypertension detection and management.
  • With an estimated 75 million American adults diagnosed with high blood pressure, the potential impact of LiveCare Inc.'s new device is considerable.

ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100’s Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications

Retrieved on: 
Wednesday, February 28, 2024
Pyroptosis, Liver, Macrophage, Inflammation, Cell death, ASC, Cardiovascular disease, Cancer, NLRP3, Syndrome, WAT, Breast, Dyslipidemia, Therapy, Hypertension, Super Meat Boy, Insulin resistance, Adipose tissue, Inflammasome, Tissue, DSM-IV codes, Research, Pharmaceutical industry

Pyroptosis results in systemic release of inflammatory cytokines, IL-1β and IL-18, and ASC specks, which perpetuates and spreads inflammation to other tissues leading to the metabolic disturbances associated with obesity.

Key Points: 
  • Pyroptosis results in systemic release of inflammatory cytokines, IL-1β and IL-18, and ASC specks, which perpetuates and spreads inflammation to other tissues leading to the metabolic disturbances associated with obesity.
  • ZyVersa is developing Inflammasome ASC Inhibitor IC 100, designed to inhibit formation of multiple types of inflammasomes and their associated ASC specks to attenuate initiation and perpetuation of damaging inflammation.
  • WESTON, Fla., Feb. 28, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, highlights data published in Nature reinforcing IC 100’s rationale for inhibiting ASC and ASC Specks to attenuate damaging inflammation associated with various conditions, including obesity and its complications.
  • Likewise, IC 100 uniquely inhibits ASC specks to attenuate spread and perpetuation of damaging inflammation.” To review a white paper summarizing the mechanism of action and preclinical data for IC 100, Click Here .

Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with AVIM Therapy for Over 3 Years

Retrieved on: 
Monday, February 26, 2024
Blood pressure, Innovation, Senior, Mercury (element), Beat (music), Orchestra, Risk, Hypertension, Patient, Pharmaceutical industry

“These new long-term follow up data demonstrate AVIM therapy’s ability to drive a substantial and sustained reduction in 24-hour ambulatory systolic blood pressure, the gold standard, and most accurate measure of hypertension.

Key Points: 
  • “These new long-term follow up data demonstrate AVIM therapy’s ability to drive a substantial and sustained reduction in 24-hour ambulatory systolic blood pressure, the gold standard, and most accurate measure of hypertension.
  • Each patient’s aSBP was measured an average of 3.6 (±0.6) years following original initiation of AVIM therapy.
  • AVIM therapy is an investigational patented bioelectronic therapy, administered using a standard dual-chamber pacemaker, designed to immediately, substantially and persistently reduce blood pressure.
  • Orchestra BioMed and Medtronic plc (NYSE: MDT) (“Medtronic”) formed a strategic collaboration for the development and commercialization of AVIM therapy for hypertensive pacemaker patients in July 2022.